Hypertension (HTN) is a global health problem and a leading risk factor for cardiovascular
disease (CVD) morbidity and mortality. The hemodynamic overload from HTN causes left …

Background Antihypertensive drugs may differ in their ability to reduce LV mass. Covariates
other than drug selection, such as pretreatment LV mass, body weight, the magnitude of …

Background The different geometric patterns of the left ventricle may or may not coexist with
chamber dilatation. The prognostic impact of such a combination is unclear. Methods and …

In numerous studies, left ventricular hypertrophy (LVH) has been clearly established to be a
strong blood pressure (BP) independent risk factor for cardiovascular morbidity and …

Objective: The primary aim of the present study was to determine the prevalence of left
ventricular hypertrophy (LVH) in hypertensive patients with the use of different threshold …

Background—It is still unclear whether substantial regression of hypertensive left ventricular
hypertrophy (LVH) and normalization of chamber geometry are associated with improved left …

Blood pressure–lowering therapy reduces left ventricular mass, but the question of whether
differences exist among drug classes has not been fully resolved. Our aim was to compare …

Background Evidence-based medicine should provide clear and unbiased information to
clinicians. We conducted an analysis on published randomized trials evaluating the effects …

Background and aim. The impact of aging on the relationship between left ventricular (LV)
mass/geometry and diastolic function as assessed by updated echocardiographic methods …

Background: Left ventricular hypertrophy [LVH, high left ventricular mass (LVM)] is
traditionally classified as concentric or eccentric based on left ventricular relative wall …